Literature DB >> 28515298

Crimean-Congo Hemorrhagic Fever Virus Nucleocapsid Protein Augments mRNA Translation.

Subbiah Jeeva1, Erdong Cheng2, Safder S Ganaie2, Mohammad A Mir3.   

Abstract

Crimean-Congo hemorrhagic fever virus (CCHFV) is a tick-borne Nairovirus of the Bunyaviridae family, causing severe illness with high mortality rates in humans. Here, we demonstrate that CCHFV nucleocapsid protein (CCHFV-NP) augments mRNA translation. CCHFV-NP binds to the viral mRNA 5' untranslated region (UTR) with high affinity. It facilitates the translation of reporter mRNA both in vivo and in vitro with the assistance of the viral mRNA 5' UTR. CCHFV-NP equally favors the translation of both capped and uncapped mRNAs, demonstrating the independence of this translation strategy on the 5' cap. Unlike the canonical host translation machinery, inhibition of eIF4F complex, an amalgam of three initiation factors, eIF4A, eIF4G, and eIF4E, by the chemical inhibitor 4E1RCat did not impact the CCHFV-NP-mediated translation mechanism. However, the proteolytic degradation of eIF4G alone by the human rhinovirus 2A protease abrogated this translation strategy. Our results demonstrate that eIF4F complex formation is not required but eIF4G plays a critical role in this translation mechanism. Our results suggest that CCHFV has adopted a unique translation mechanism to facilitate the translation of viral mRNAs in the host cell cytoplasm where cellular transcripts are competing for the same translation apparatus.IMPORTANCE Crimean-Congo hemorrhagic fever, a highly contagious viral disease endemic to more than 30 countries, has limited treatment options. Our results demonstrate that NP favors the translation of a reporter mRNA harboring the viral mRNA 5' UTR. It is highly likely that CCHFV uses an NP-mediated translation strategy for the rapid synthesis of viral proteins during the course of infection. Shutdown of this translation mechanism might selectively impact viral protein synthesis, suggesting that an NP-mediated translation strategy is a target for therapeutic intervention against this viral disease.
Copyright © 2017 American Society for Microbiology.

Entities:  

Keywords:  bunyavirus; negative-strand RNA virus; nucleocapsid protein; translation

Mesh:

Substances:

Year:  2017        PMID: 28515298      PMCID: PMC5512247          DOI: 10.1128/JVI.00636-17

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  33 in total

1.  Ribosomal protein S19-binding domain provides insights into hantavirus nucleocapsid protein-mediated translation initiation mechanism.

Authors:  Safder S Ganaie; Absarul Haque; Erdong Cheng; Tania S Bonny; Nilshad N Salim; Mohammad A Mir
Journal:  Biochem J       Date:  2014-11-15       Impact factor: 3.857

2.  The triplet repeats of the Sin Nombre hantavirus 5' untranslated region are sufficient in cis for nucleocapsid-mediated translation initiation.

Authors:  Mohammad A Mir; Antonito T Panganiban
Journal:  J Virol       Date:  2010-06-23       Impact factor: 5.103

3.  Reversing chemoresistance by small molecule inhibition of the translation initiation complex eIF4F.

Authors:  Regina Cencic; David R Hall; Francis Robert; Yuhong Du; Jaeki Min; Lian Li; Min Qui; Iestyn Lewis; Serdar Kurtkaya; Ray Dingledine; Haian Fu; Dima Kozakov; Sandor Vajda; Jerry Pelletier
Journal:  Proc Natl Acad Sci U S A       Date:  2010-12-29       Impact factor: 11.205

4.  Autophagic clearance of Sin Nombre hantavirus glycoprotein Gn promotes virus replication in cells.

Authors:  Islam T M Hussein; Erdong Cheng; Safder S Ganaie; Michael J Werle; Sheema Sheema; Absarul Haque; Muhammad A Mir
Journal:  J Virol       Date:  2012-05-02       Impact factor: 5.103

5.  The eIF4G-eIF4E complex is the target for direct cleavage by the rhinovirus 2A proteinase.

Authors:  A Haghighat; Y Svitkin; I Novoa; E Kuechler; T Skern; N Sonenberg
Journal:  J Virol       Date:  1996-12       Impact factor: 5.103

Review 6.  Crimean-Congo hemorrhagic fever.

Authors:  Chris A Whitehouse
Journal:  Antiviral Res       Date:  2004-12       Impact factor: 5.970

7.  Inhibition of HeLa cell protein synthesis following poliovirus infection correlates with the proteolysis of a 220,000-dalton polypeptide associated with eucaryotic initiation factor 3 and a cap binding protein complex.

Authors:  D Etchison; S C Milburn; I Edery; N Sonenberg; J W Hershey
Journal:  J Biol Chem       Date:  1982-12-25       Impact factor: 5.157

8.  A protein that replaces the entire cellular eIF4F complex.

Authors:  Mohammad A Mir; Antonito T Panganiban
Journal:  EMBO J       Date:  2008-10-30       Impact factor: 11.598

9.  A two-pronged strategy to suppress host protein synthesis by SARS coronavirus Nsp1 protein.

Authors:  Wataru Kamitani; Cheng Huang; Krishna Narayanan; Kumari G Lokugamage; Shinji Makino
Journal:  Nat Struct Mol Biol       Date:  2009-10-18       Impact factor: 15.369

10.  Heat Shock Protein 70 Family Members Interact with Crimean-Congo Hemorrhagic Fever Virus and Hazara Virus Nucleocapsid Proteins and Perform a Functional Role in the Nairovirus Replication Cycle.

Authors:  Rebecca Surtees; Stuart D Dowall; Amelia Shaw; Stuart Armstrong; Roger Hewson; Miles W Carroll; Jamel Mankouri; Thomas A Edwards; Julian A Hiscox; John N Barr
Journal:  J Virol       Date:  2016-09-29       Impact factor: 5.103

View more
  9 in total

Review 1.  The nucleocapsid protein of hantaviruses: much more than a genome-wrapping protein.

Authors:  Monika Reuter; Detlev H Krüger
Journal:  Virus Genes       Date:  2017-11-20       Impact factor: 2.332

2.  Hantavirus RdRp Requires a Host Cell Factor for Cap Snatching.

Authors:  Subbiah Jeeva; Sheema Mir; Adrain Velasquez; Brandy A Weathers; Aljona Leka; Sharon Wu; Ariga Tahmasian Sevarany; Mohammad Mir
Journal:  J Virol       Date:  2019-02-19       Impact factor: 5.103

3.  Crimean-Congo hemorrhagic fever virus nucleocapsid protein harbors distinct RNA-binding sites in the stalk and head domains.

Authors:  Subbiah Jeeva; Sheema Mir; Adrain Velasquez; Jacquelyn Ragan; Aljona Leka; Sharon Wu; Ariga Tahmasian Sevarany; Austin D Royster; Nicholas A Almeida; Fion Chan; Lea O'Brien; Mohammad Ayoub Mir
Journal:  J Biol Chem       Date:  2019-02-05       Impact factor: 5.157

Review 4.  Structural and functional similarities in bunyaviruses: Perspectives for pan-bunya antivirals.

Authors:  Sebastiaan Ter Horst; Nádia Conceição-Neto; Johan Neyts; Joana Rocha-Pereira
Journal:  Rev Med Virol       Date:  2019-02-11       Impact factor: 6.989

5.  Immunocompetent mouse model for Crimean-Congo hemorrhagic fever virus.

Authors:  David W Hawman; Kimberly Meade-White; Shanna Leventhal; Friederike Feldmann; Atsushi Okumura; Brian Smith; Dana Scott; Heinz Feldmann
Journal:  Elife       Date:  2021-01-08       Impact factor: 8.140

6.  A novel approach for the purification of aggregation prone proteins.

Authors:  Austin Royster; Sheema Mir; Mohammad Ayoub Mir
Journal:  PLoS One       Date:  2021-11-22       Impact factor: 3.240

7.  A comprehensive list of the Bunyavirales replication promoters reveals a unique promoter structure in Nairoviridae differing from other virus families.

Authors:  Yutaro Neriya; Shohei Kojima; Arata Sakiyama; Mai Kishimoto; Takao Iketani; Tadashi Watanabe; Yuichi Abe; Hiroshi Shimoda; Keisuke Nakagawa; Takaaki Koma; Yusuke Matsumoto
Journal:  Sci Rep       Date:  2022-08-09       Impact factor: 4.996

8.  Bunyaviral N Proteins Localize at RNA Processing Bodies and Stress Granules: The Enigma of Cytoplasmic Sources of Capped RNA for Cap Snatching.

Authors:  Min Xu; Magdalena Mazur; Nigel Gulickx; Hao Hong; Hein Overmars; Xiaorong Tao; Richard Kormelink
Journal:  Viruses       Date:  2022-07-29       Impact factor: 5.818

9.  In Silico Drug Repurposing by Structural Alteration after Induced Fit: Discovery of a Candidate Agent for Recovery of Nucleotide Excision Repair in Xeroderma Pigmentosum Group D Mutant (R683W).

Authors:  Yutaka Takaoka; Mika Ohta; Satoshi Tateishi; Aki Sugano; Eiji Nakano; Kenji Miura; Takashi Suzuki; Chikako Nishigori
Journal:  Biomedicines       Date:  2021-03-03
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.